Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 8/20 | 0.40 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30995282 | 1.00 | P2RX7 (0.40) | P2RX7P2RY12SLC6A9ALDH1A1MAPT | |
| SCHEMBL27213887 | 0.93 | P2RX7 (0.41) | P2RX7P2RY12SLC6A9ALDH1A1MAPT | |
| SCHEMBL27213733 | 0.93 | P2RX7 (0.39) | P2RX7P2RY12SLC6A9ALDH1A1MAPT | |
| SCHEMBL29317993 | 0.93 | P2RX7 (0.39) | P2RX7P2RY12SLC6A9ALDH1A1MAPT | |
| SCHEMBL29317998 | 0.93 | P2RX7 (0.41) | P2RX7P2RY12SLC6A9ALDH1A1MAPT | |
| SCHEMBL27213716 | 0.92 | P2RX7 (0.39) | P2RX7P2RY12SLC6A9ALDH1A1MAPT | |
| SCHEMBL27390891 | 0.92 | P2RX7 (0.39) | P2RX7P2RY12SLC6A9ALDH1A1MAPT | |
| SCHEMBL27213785 | 0.92 | P2RX7 (0.40) | P2RX7P2RY12SLC6A9ALDH1A1MAPT | |
| SCHEMBL27391240 | 0.92 | P2RX7 (0.40) | P2RX7P2RY12SLC6A9ALDH1A1MAPT | |
| SCHEMBL30995348 | 0.91 | P2RX7 (0.40) | P2RX7P2RY12SLC6A9ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | HSD17B13, HSD17B3, HSD17B1 | P2RX7 4636/4885P2RY12 4167/4885SLC6A9 4223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.